In vitro evaluation of A-56619 and A-56620, two new quinolones.
AUTOR(ES)
Barry, A L
RESUMO
The in vitro activities of two new aryl-fluoroquinolones (A-56619 and A-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. All six quinolones had broad spectra of antibacterial activity; the streptococci, Pseudomonas maltophilia, and Pseudomonas cepacia were the least susceptible. A-56619, A-56620, and chloramphenicol had similar activity against anaerobic bacteria. With both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. By regression analysis, A-56619 MICs correlated best with ofloxacin MICs and A-56620 was most similar to ciprofloxacin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=180360Documentos Relacionados
- In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.
- In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
- In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
- In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
- In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
